InsidersTradesSigma
No insider purchase over the last 90 days. The latest was filed 15 Sept 2025.
Track the Rapport Therapeutics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €1.6bn. The latest transaction was disclosed on 1 October 2026 (Cession). Among the most active insiders: Ceesay Abraham. The full history is openly available.
71
Insider Decl.
n/a
Thresholds
€1M
6 ops.
Buy Volume
€25M
51 ops.
Sell Volume
Since the insiders bought
- +26.1%Entry US$26.19 · Close 29 Sept 2026 US$33.02
- +26.1%Entry US$26.19 · Close 29 Sept 2026 US$33.02
- +39.0%Entry US$23.76 · Close 29 Sept 2026 US$33.02
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Rapport Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.88.
47Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 October 2026
Declarations71 total
7,925 shares@ US$33.0364Common StockSEC:0001193125-26-410734:0
2,075 shares@ US$33.7556Common StockSEC:0001193125-26-410734:1
10,000 shares@ US$33.020.021% mcap45.1% of flowCommonSEC144:0001950047-26-009884
1,952 shares@ US$39.05230.0047% mcap1.3% of flowCommon StockSEC:0001193125-26-401017:0
215 shares@ US$39.86020.0005% mcap0.1% of flowCommon StockSEC:0001193125-26-401017:1
43 shares@ US$41.050.0001% mcap0.0% of flowCommon StockSEC:0001193125-26-401017:2
7,141 shares@ US$45.5550.020% mcap5.6% of flowCommon StockSEC:0001193125-26-386436:0
1,069 shares@ US$46.01470.0030% mcap0.8% of flowCommon StockSEC:0001193125-26-386436:1
18,921 shares@ US$49.57230.056% mcap16.1% of flowCommon StockSEC:0001193125-26-368285:0
13,160 shares@ US$49.99830.039% mcap15.1% of flowCommon StockSEC:0001193125-26-368244:0
20,799 shares@ US$50.31110.063% mcap24.0% of flowCommon StockSEC:0001193125-26-368244:1
16,201 shares@ US$51.05760.050% mcap19.0% of flowCommon StockSEC:0001193125-26-368244:2
37,000 shares@ US$49.330.11% mcap73.6% of flowCommonSEC144:0001950047-26-008670
11,472 shares@ US$48.240.033% mcap22.3% of flowCommonSEC144:0001950047-26-008594
404 shares@ US$49.900.0012% mcap0.5% of flowCommon StockSEC:0001193125-26-359189:0
2,092 shares@ US$49.010.0062% mcap4.2% of flowCommonSEC144:0001950047-26-008426
14,171 shares@ US$45.97360.039% mcap11.3% of flowCommon StockSEC:0001193125-26-346995:0
8,370 shares@ US$46.74790.024% mcap6.8% of flowCommon StockSEC:0001193125-26-346995:1
3,664 shares@ US$46.89880.010% mcap3.0% of flowCommon StockSEC:0001193125-26-346995:2
19,500 shares@ US$48.04340.057% mcap16.2% of flowCommon StockSEC:0001193125-26-346995:3
5,794 shares@ US$48.62290.017% mcap4.9% of flowCommon StockSEC:0001193125-26-346995:4
2,203 shares@ US$42.1070.0057% mcap1.6% of flowCommon StockSEC:0001193125-26-323637:0
7 shares@ US$42.7350.0000% mcap0.0% of flowCommon StockSEC:0001193125-26-323637:1
5,481 shares@ US$39.72170.013% mcap3.8% of flowCommon StockSEC:0001193125-26-304786:0
2,729 shares@ US$40.57240.0068% mcap1.9% of flowCommon StockSEC:0001193125-26-304786:1
25 of 71 declarations
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a company focused on developing innovative treatments for neurological diseases. It is listed on the XNAS market.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations